Funded Startups in Nice
Across the 13 most recent funded startups listed in Nice, the largest disclosed round is Therapixel’s $16M on 2022-05-12.
Across the 13 most recent funded startups listed in Nice, the largest disclosed round is Therapixel’s $16M on 2022-05-12. That level is an outlier versus other disclosed amounts in the table, where only Izicap’s $15M (2022-11-03) is close; most other disclosed rounds cluster between $1M and $10M (e.g., Delicity $1M on 2024-09-20, Firecell $7M on 2024-03-24, Bodyguard $10M on 2022-03-10).
The dated entries also show tight temporal concentration: the most recent 13 rounds span 2021-01-20 (Vulog) through 2024-09-20 (Delicity), with three rounds in late 2022 (2022-09-22, 2022-11-03, 2022-11-23) and three more in 2023 (2023-10-03, 2023-12-11, 2023-12-14). Sector-wise, “Series Unknown” appears 5 times (Firecell 2024-03-24, Inalve 2023-12-11, Oghji 2023-10-03, Native Spaces 2023-06-08, Izicap 2022-11-03), while stages are otherwise split across Seed (Delicity, Fundbot, Roca Therapeutics), Pre-Seed (Beau), Series A (Bodyguard), Series B (Therapixel), and Series C (Vulog).
Most recent rounds
13 shownRelated listings
Frequently asked
What do the largest disclosed rounds in Nice look like compared with the rest of the recent entries?
Therapixel raised the largest disclosed amount at $16M (2022-05-12), with Izicap close behind at $15M (2022-11-03). Every other disclosed round in the list is $10M or below (e.g., Bodyguard $10M on 2022-03-10; Firecell $7M on 2024-03-24; Delicity $1M on 2024-09-20).
Do the rounds cluster in a narrow time window rather than spreading evenly across 2021–2024?
Yes. Late 2022 is busy, with three entries tightly grouped around September–November 2022: Roca Therapeutics (2022-09-22, undisclosed), Izicap ($15M on 2022-11-03), and Livmed's ($5M on 2022-11-23). There is also a smaller 2023 cluster at year-end (Fundbot $2M on 2023-12-14; Inalve $2M on 2023-12-11).
Which stage labels dominate, and how often is the round stage unclear?
“Series Unknown” is the most frequent stage designation at 5 of the 13 rows (Firecell, Inalve, Oghji, Native Spaces, Izicap). Disclosed non-unknown stages then include Seed (Delicity 2024-09-20 $1M; Fundbot 2023-12-14 $2M; Roca Therapeutics 2022-09-22 undisclosed), and single instances each of Pre-Seed (Beau $100K on 2021-08-10), Series A (Bodyguard $10M on 2022-03-10), Series B (Therapixel $16M on 2022-05-12), and Series C (Vulog $32M on 2021-01-20).
Where are the outliers in disclosed amount, including the impact of undisclosed rounds?
Vulog’s $32M (2021-01-20) is an amount outlier on the high end compared with the majority of disclosed rounds that sit at $10M or below. On the low end, Beau’s $100K (2021-08-10) is the smallest disclosed amount; Roca Therapeutics is the main undisclosed entry (2022-09-22, sector Biotechnology), making comparisons for that row incomplete.
What’s the most recent funding signal in this list, and does it match the largest rounds by amount?
The most recent row is Delicity, Seed, on 2024-09-20 with a $1M round. That is materially smaller than the largest disclosed rounds in the table, where Therapixel ($16M on 2022-05-12) and Izicap ($15M on 2022-11-03) dominate the upper end of disclosed amounts.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.